B-intervention	0	11	Palbociclib
I-intervention	12	20	Combined
I-intervention	21	25	with
I-intervention	26	37	Fulvestrant
O	38	40	in
O	41	54	Premenopausal
O	55	60	Women
O	61	65	with
O	66	74	Advanced
O	75	81	Breast
O	82	88	Cancer
O	89	92	and
O	93	98	Prior
O	99	110	Progression
O	111	113	on
O	114	123	Endocrine
O	124	131	Therapy
O	131	132	:
O	133	139	PALOMA
O	139	140	-
O	140	141	3
O	142	149	Results
O	149	150	.

O	151	154	The
O	155	163	efficacy
O	164	167	and
O	168	174	safety
O	175	177	of
O	178	189	palbociclib
O	189	190	,
O	191	192	a
O	193	199	cyclin
O	199	200	-
O	200	209	dependent
O	210	216	kinase
O	217	218	4
O	218	219	/
O	219	220	6
O	221	230	inhibitor
O	230	231	,
O	232	240	combined
O	241	245	with
O	246	257	fulvestrant
O	258	261	and
O	262	271	goserelin
O	272	275	was
O	276	284	assessed
O	285	287	in
O	288	301	premenopausal
O	302	307	women
O	308	312	with
O	313	321	advanced
O	322	328	breast
O	329	335	cancer
O	336	337	(
O	337	340	ABC
O	340	341	)
O	342	345	who
O	346	349	had
O	350	360	progressed
O	361	363	on
O	364	369	prior
O	370	379	endocrine
O	380	387	therapy
O	388	389	(
O	389	391	ET
O	391	392	)
O	392	393	.

O	394	397	One
O	398	405	hundred
O	406	411	eight
O	412	425	premenopausal
O	426	435	endocrine
O	435	436	-
O	436	446	refractory
O	447	452	women
O	453	454	≥
O	454	456	18
O	457	462	years
O	463	467	with
O	468	475	hormone
O	476	484	receptor
O	484	485	-
O	485	493	positive
O	494	495	(
O	495	497	HR
O	497	498	+
O	498	499	)
O	499	500	/
O	500	505	human
O	506	515	epidermal
O	516	522	growth
O	523	529	factor
O	530	538	receptor
O	539	540	2
O	540	541	-
O	541	549	negative
O	550	551	(
O	551	555	HER2
O	555	556	-
O	556	557	)
O	558	561	ABC
O	562	566	were
O	567	572	among
B-total-participants	573	576	521
O	577	582	women
O	583	593	randomized
O	594	595	2
O	595	596	:
O	596	597	1
O	598	599	(
B-intervention-participants	599	602	347
O	602	603	:
B-control-participants	603	606	174
O	606	607	)
O	608	610	to
O	611	622	fulvestrant
O	623	624	(
O	624	627	500
O	628	630	mg
O	630	631	)
O	632	633	±
O	634	643	goserelin
O	644	648	with
O	649	655	either
O	656	667	palbociclib
O	668	669	(
O	669	672	125
O	673	675	mg
O	675	676	/
O	676	679	day
O	680	686	orally
O	686	687	,
O	688	689	3
O	690	695	weeks
O	696	698	on
O	698	699	,
O	700	701	1
O	702	706	week
O	707	710	off
O	710	711	)
O	712	714	or
B-control	715	722	placebo
O	722	723	.

O	724	728	This
O	729	737	analysis
O	738	746	assessed
O	747	754	whether
O	755	758	the
O	759	766	overall
O	767	776	tolerable
O	777	783	safety
O	784	791	profile
O	792	795	and
O	796	807	significant
O	808	819	progression
O	819	820	-
O	820	824	free
O	825	833	survival
O	834	835	(
O	835	838	PFS
O	838	839	)
O	840	851	improvement
O	852	860	extended
O	861	863	to
O	864	877	premenopausal
O	878	883	women
O	883	884	.

O	885	894	Potential
O	895	899	drug
O	899	900	-
O	900	904	drug
O	905	917	interactions
O	918	919	(
O	919	923	DDIs
O	923	924	)
O	925	928	and
O	929	936	ovarian
O	937	948	suppression
O	949	953	with
O	954	963	goserelin
O	964	968	were
O	969	977	assessed
O	978	981	via
O	982	988	plasma
O	989	1005	pharmacokinetics
O	1006	1009	and
O	1010	1021	biochemical
O	1022	1030	analyses
O	1030	1031	,
O	1032	1044	respectively
O	1044	1045	.

O	1046	1047	(
O	1047	1061	ClinicalTrials
O	1061	1062	.
O	1063	1066	gov
O	1067	1077	identifier
O	1077	1078	:
O	1079	1090	NCT01942135
O	1090	1091	)
O	1092	1099	RESULTS
O	1099	1100	:
B-outcome	1101	1107	Median
I-outcome	1108	1111	PFS
O	1112	1115	for
O	1116	1129	premenopausal
O	1130	1135	women
O	1136	1138	in
O	1139	1142	the
O	1143	1154	palbociclib
O	1155	1156	(
O	1156	1157	n
O	1158	1159	=
B-iv-bin-abs	1160	1162	72
O	1162	1163	)
O	1164	1170	versus
O	1171	1178	placebo
O	1179	1182	arm
O	1183	1184	(
O	1184	1185	n
O	1186	1187	=
B-cv-bin-abs	1188	1190	36
O	1190	1191	)
O	1192	1195	was
B-iv-cont-median	1196	1197	9
I-iv-cont-median	1197	1198	.
I-iv-cont-median	1198	1199	5
O	1200	1206	versus
B-cv-cont-median	1207	1208	5
I-cv-cont-median	1208	1209	.
I-cv-cont-median	1209	1210	6
I-cv-cont-median	1211	1217	months
O	1217	1218	,
O	1219	1231	respectively
O	1232	1233	(
O	1233	1239	hazard
O	1240	1245	ratio
O	1245	1246	,
O	1247	1248	0
O	1248	1249	.
O	1249	1251	50
O	1251	1252	,
O	1253	1255	95
O	1255	1256	%
O	1257	1267	confidence
O	1268	1276	interval
O	1276	1277	:
O	1278	1279	0
O	1279	1280	.
O	1280	1282	29
O	1282	1283	-
O	1283	1284	0
O	1284	1285	.
O	1285	1287	87
O	1287	1288	)
O	1288	1289	,
O	1290	1293	and
O	1294	1304	consistent
O	1305	1309	with
O	1310	1313	the
O	1314	1325	significant
O	1326	1329	PFS
O	1330	1341	improvement
O	1342	1344	in
O	1345	1348	the
O	1349	1353	same
O	1354	1358	arms
O	1359	1362	for
O	1363	1377	postmenopausal
O	1378	1383	women
O	1383	1384	.

B-outcome	1385	1388	Any
I-outcome	1388	1389	-
I-outcome	1389	1394	grade
I-outcome	1395	1398	and
I-outcome	1399	1404	grade
I-outcome	1405	1406	≤
I-outcome	1406	1407	3
I-outcome	1408	1419	neutropenia
O	1419	1420	,
B-outcome	1421	1431	leukopenia
O	1431	1432	,
O	1433	1436	and
B-outcome	1437	1447	infections
O	1448	1452	were
O	1453	1458	among
O	1459	1462	the
O	1463	1467	most
O	1468	1476	frequent
B-outcome	1477	1484	adverse
I-outcome	1485	1491	events
O	1492	1500	reported
O	1501	1503	in
O	1504	1507	the
O	1508	1519	palbociclib
O	1520	1523	arm
O	1524	1528	with
O	1529	1539	concurrent
O	1540	1549	goserelin
O	1550	1564	administration
O	1564	1565	.

B-outcome	1566	1573	Hormone
I-outcome	1574	1588	concentrations
O	1589	1593	were
O	1594	1601	similar
O	1602	1609	between
O	1610	1619	treatment
O	1620	1624	arms
O	1625	1628	and
O	1629	1638	confirmed
O	1639	1648	sustained
O	1649	1656	ovarian
O	1657	1668	suppression
O	1668	1669	.

O	1670	1680	Clinically
O	1681	1689	relevant
O	1690	1694	DDIs
O	1695	1699	were
O	1700	1703	not
O	1704	1712	observed
O	1712	1713	.

O	1714	1725	Palbociclib
O	1726	1734	combined
O	1735	1739	with
O	1740	1751	fulvestrant
O	1752	1755	and
O	1756	1765	goserelin
O	1766	1769	was
O	1770	1772	an
B-outcome	1773	1782	effective
O	1783	1786	and
B-outcome	1787	1791	well
I-outcome	1791	1792	-
I-outcome	1792	1801	tolerated
O	1802	1811	treatment
O	1812	1815	for
O	1816	1829	premenopausal
O	1830	1835	women
O	1836	1840	with
O	1841	1846	prior
O	1847	1856	endocrine
O	1856	1857	-
O	1857	1866	resistant
O	1867	1869	HR
O	1869	1870	+
O	1870	1871	/
O	1871	1875	HER2
O	1875	1876	-
O	1877	1880	ABC
O	1880	1881	.

O	1882	1891	Inclusion
O	1892	1894	of
O	1895	1899	both
O	1900	1913	premenopausal
O	1914	1917	and
O	1918	1932	postmenopausal
O	1933	1938	women
O	1939	1941	in
O	1942	1949	pivotal
O	1950	1961	combination
O	1962	1964	ET
O	1965	1971	trials
O	1972	1983	facilitates
O	1984	1990	access
O	1991	1993	to
O	1994	1999	novel
O	2000	2005	drugs
O	2006	2009	for
O	2010	2015	young
O	2016	2021	women
O	2022	2025	and
O	2026	2032	should
O	2033	2035	be
O	2036	2046	considered
O	2047	2049	as
O	2050	2051	a
O	2052	2055	new
O	2056	2064	standard
O	2065	2068	for
O	2069	2077	clinical
O	2078	2083	trial
O	2084	2090	design
O	2090	2091	.

O	2092	2098	PALOMA
O	2098	2099	-
O	2099	2100	3
O	2100	2101	,
O	2102	2105	the
O	2106	2111	first
O	2112	2126	registrational
O	2127	2132	study
O	2133	2135	to
O	2136	2143	include
O	2144	2157	premenopausal
O	2158	2163	women
O	2164	2166	in
O	2167	2168	a
O	2169	2174	trial
O	2175	2188	investigating
O	2189	2190	a
O	2191	2195	CDK4
O	2195	2196	/
O	2196	2197	6
O	2198	2207	inhibitor
O	2208	2216	combined
O	2217	2221	with
O	2222	2231	endocrine
O	2232	2239	therapy
O	2239	2240	,
O	2241	2244	has
O	2245	2248	the
O	2249	2256	largest
O	2257	2270	premenopausal
O	2271	2277	cohort
O	2278	2286	reported
O	2287	2289	in
O	2290	2292	an
O	2293	2302	endocrine
O	2302	2303	-
O	2303	2312	resistant
O	2313	2320	setting
O	2320	2321	.

O	2322	2324	In
O	2325	2335	pretreated
O	2336	2349	premenopausal
O	2350	2355	women
O	2356	2360	with
O	2361	2368	hormone
O	2369	2377	receptor
O	2377	2378	-
O	2378	2386	positive
O	2387	2395	advanced
O	2396	2402	breast
O	2403	2409	cancer
O	2409	2410	,
O	2411	2422	palbociclib
O	2423	2427	plus
O	2428	2439	fulvestrant
O	2440	2443	and
O	2444	2453	goserelin
O	2454	2455	(
O	2455	2466	luteinizing
O	2467	2474	hormone
O	2474	2475	-
O	2475	2484	releasing
O	2485	2492	hormone
O	2493	2494	[
O	2494	2498	LHRH
O	2498	2499	]
O	2500	2507	agonist
O	2507	2508	)
O	2509	2518	treatment
O	2519	2525	almost
O	2526	2533	doubled
O	2534	2540	median
O	2541	2552	progression
O	2552	2553	-
O	2553	2557	free
O	2558	2566	survival
O	2567	2568	(
O	2568	2571	PFS
O	2571	2572	)
O	2573	2576	and
O	2577	2590	significantly
O	2591	2600	increased
O	2601	2604	the
O	2605	2614	objective
O	2615	2623	response
O	2624	2628	rate
O	2629	2635	versus
O	2636	2645	endocrine
O	2646	2657	monotherapy
O	2657	2658	,
O	2659	2668	achieving
O	2669	2676	results
O	2677	2687	comparable
O	2688	2690	to
O	2691	2696	those
O	2697	2705	reported
O	2706	2709	for
O	2710	2722	chemotherapy
O	2723	2730	without
O	2731	2741	apparently
O	2742	2753	interfering
O	2754	2758	with
O	2759	2763	LHRH
O	2764	2771	agonist
O	2771	2772	-
O	2772	2779	induced
O	2780	2787	ovarian
O	2788	2799	suppression
O	2799	2800	.

O	2801	2804	The
O	2805	2816	significant
O	2817	2820	PFS
O	2821	2825	gain
O	2826	2829	and
O	2830	2839	tolerable
O	2840	2846	safety
O	2847	2854	profile
O	2855	2863	strongly
O	2864	2871	support
O	2872	2875	use
O	2876	2878	of
O	2879	2883	this
O	2884	2891	regimen
O	2892	2894	in
O	2895	2908	premenopausal
O	2909	2914	women
O	2915	2919	with
O	2920	2929	endocrine
O	2929	2930	-
O	2930	2939	resistant
O	2940	2947	disease
O	2948	2951	who
O	2952	2957	could
O	2958	2966	possibly
O	2967	2972	delay
O	2973	2985	chemotherapy
O	2985	2986	.
